Glioblastoma Clinical Trials in Durham, North Carolina

7 studies are recruiting for glioblastoma in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Targeted Pediatric High-Grade Glioma Therapy

   The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

   Stage

   Not phased

   Ages

   1 to 39

   Site

   Duke University Health System, Durham, North Carolina

   Locations

   22 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05839379 on ClinicalTrials.gov

2. EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Gliobla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   102 in total

   Run by

   NovoCure GmbH

   See if you can join NCT06556563 on ClinicalTrials.gov

3. A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

   Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnose…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   63 in total

   Run by

   Global Coalition for Adaptive Research

   See if you can join NCT03970447 on ClinicalTrials.gov

4. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

   The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   Duke University Health System, Durham, North Carolina

   Locations

   18 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT06333899 on ClinicalTrials.gov

5. Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

   The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib …

   Stage

   Phase 2

   Ages

   1 to 39

   Site

   Duke University Health System, Durham, North Carolina

   Locations

   20 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05843253 on ClinicalTrials.gov

6. Key Longitudinal Associations With Risk and Glioblastoma Outcomes

   The goal of this observational study is to find out what factors affect the health and risks in adults with glioblastoma (GBM), a grade 4 brain cancer. The main questions it aims to answer are: * How do genetic and immune system factors impact survival and quality of life in GBM patients? * What oc…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT06625684 on ClinicalTrials.gov

7. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

   The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   8 in total

   Run by

   Orbus Therapeutics, Inc.

   See if you can join NCT05879367 on ClinicalTrials.gov